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Inflammatory Bowel Disease (IBD) in pregnancy: analysis 
of the possible effects of the disease on the fetus and the 
newborn and therapeutic approaches
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enterology and Endoscopy Unit, Cefalù, Italy; 3 DICHIRONS Department, Faculty of Medicine, University of Palermo, Italy; 
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Summary. The Inflammatory Bowel Diseases are a group of inflammatory diseases characterized by the 
presence of chronic inflammation, in the absence of infectious etiology. The two most well-known diseases 
in this group are: Crohn’s disease (CD) and Ulcerative Colitis (UC). In cases where it is not possible to 
distinguish between CD and UC, it is called Indeterminate Colitis. Inflammatory Bowel Diseases (IBD) 
can affect women pregnant. The causes of IBD are unknown, and the clinical course of the disease is char-
acterized by phases of activity and remission. UC is a chronic inflammation of the mucosa of the colon and 
involving predominantly the left colon and rectum. It is associated with presence of blood and mucus in 
the stool, diarrhea and anemia. Characteristically, CD involves entire gastrointestinal tract, from the mouth 
to the anus. In CD, the inflammatory infiltrate involves the entire intestinal wall. Clinically manifested by 
abdominal pain, diarrhea, loss of appetite and weight loss. The complications are stenosis , fistulas, abscess-
es, and perianal involvement. In IBD TNF-alpha and proinflammatory cytokines are overexpressed. The 
analysis of the scientific literature shows that fertility, in pregnant women suffering from IBD, is preserved. 
It shows slightly reduced for CD and ileo-anal pouch. Women with active disease at the time of conception 
have an increased risk of spontaneous abortion, preterm birth, with low birth weight and congenital malfor-
mations of the fetus. The indications for surgical treatment are the same as for non-pregnant women. The 
inactive disease or ileo-anal pouch is not a contraindication to spontaneous vaginal delivery, as is happens 
in the case of active colitis or perirectal fistulas or rectovaginal fistulas. Safe drugs during pregnancy are: 
5-aminosalicylic acid (5-ASA), steroids, 6-mercaptopurine (6MP)/Azathioprine (AZA) and Infliximab. 
Contraindicated drugs are Methotrexate and Thalidomide. In conclusion, the expectations about pregnancy, 
in women affected of IBD, is similar to the general population, especially if the conception occurs in inac-
tive phase of the disease. 
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Introduction
Over the last 20 years, in industrialized countries, 
including Italy, a continuous increase in the incidence 
of CD has been registered. Epidemiological data show 
that this disease also affects women of childbearing 
age, especially among 20-25 years.
Today we know that the disease can occur at any 
age, even around 60-70 years. UC has an annual in-
cidence of about 5-7 cases per 100,000 inhabitants. 
CD, however, has an annual incidence of 3-4 cases per 
100,000 inhabitants (1).
UC typically involves the mucosa of the rectum 
and sigmoid colon. It can also spread and affect the 
entire colon. IBD-related mucosa alterations include: 
inflammation, oedema, and severe cases of erosions or 
ulcerations. The most common symptom is proctor-
ragia or blood in the stools. Other symptoms are diar-
rhoea, the emission of mucus always associated with 
blood, urgency, tenesmus, abdominal pain in the lower 
abdomen. A constant blood loss can lead to severe 
anaemia (2). The clinical course of the disease is char-
acterized by phases of remission, or acute phases with 
acute exacerbation of the clinical symptoms. In UC we 
can also have extraintestinal manifestations. Between 
these, the most frequent involve joints, skin, eye, also 
including sclerosing cholangitis (3, 4).
CD is a chronic inflammation that can affect any 
segment of the gastrointestinal tract, from mouth to 
anus. The most common location is in the ileum and 
colon. The inflammation involves the full-thickness 
intestinal wall. The disease was named after Dr. Burrill 
B. Crohn described it for the first time in 1932. The 
causes are not yet known and the disease is charac-
terized by alternating phases of activity and remission. 
The most common symptoms are abdominal pain, 
often in the periumbilical and right upper quadrant, 
associated with diarrhoea. Frequently, loss of appetite 
and weight loss appear; fever may occur. In CD the 
intestinal wall is thickened and congested. Mucosal le-
sions have a segmental appearance; areas of inflamed 
mucosa are interspersed with areas of smooth mucosa. 
Mucosal ulcers may deepen in the intestinal wall and 
form the characteristic appearance of “cobblestones”. 
The inflammation of the entire colonic wall, can lead 
to adhesions between the intestinal loops. These adhe-
sions can correlate with the formation of colic fistulas 
(colo-cutaneous fistulas, colo-vescical fistulas, biliary-
colonic fistula, etc...). The formation of scar tissue (for 
an excessive production and accumulation of collagens 
in fibrotic disease), leads to the formation of cicatricial 
stenoses of bowel loops. This situation predisposes to 
bowel obstruction and acute abdomen.
In CD (similarly to other IBD) extraintestinal 
manifestations which may involve different organs or 
systems can occur (Tab. 1).
The severity and characteristics of IBD ex-
traintestinal manifestations depend on the extension 
and intensity of the inflammation, and the presence or 
absence of complications (5-7). The aetiology of IBD 
is still unknown; however, several etio-patgogenetic 
hypotheses have been reported. For CD, a viral origin 
has been suggested; some epidemiological data involve 
the measles virus. This virus, persisting in the intestinal 
endothelium after infection, induces an inflammatory 
response with a granulomatous vasculitis. The hypoth-
esis of a bacterial etiology refers to the mycobacterium 
avium paratuberculosis, which is the causative agent of 
‘Johne’s disease’. This disease presents clinical symptoms 
very similar to CD (8, 9). Other studies have showed 
the association of CD with the presence of serum anti-
Saccharomyces Cerevisie (10). Also, the genetic hypoth-
esis has been carefully considered. Molecular biology 
has identified specific genetic mutations in IBD. More 
specifically, on the short arm of chromosome 16 a lo-
cus, called IBD1, which makes individuals susceptible 
to CD, has been identified. Other genes involved are 
the CARD15 (known as NOD2) and others located 
in chromosome 11 and 5 (11). The gene ATG16L1, 
recently discovered, seems to reduce macrophage re-
sponse activity and favours bacterial invasion (12). 
However, not a single mutation appears to be respon-
Table 1. Common extraintestinal manifestations in IBD (5-7, 
50)
Skin lesions  erytema nodosum, pyoderma gangrenosum
Orthopedic lesions arthralgia, arthritis, sacro-ilitis, ankylosing
 spondylitis
Oral lesions mucogingivitis, aphthous stomatitis, 
 pyostomatitis vegetans
Ocular lesions  uveitis, episcleritis
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sible for the onset of the disease, but rather there are 
many other predisposing factors. The incidence of the 
disease is higher in industrialized countries, particu-
larly in urban areas and in smoking patients. Dietary 
habits appear to be one of the risk factors of the dis-
ease; especially, for those rich in fat and refined sugar 
(13-14). Similar to CD, UC has a genetic predisposi-
tion too. (15, 16).
IBD in pregnancy
During pregnancy, there are mild to moderate 
types of IBD, which are characterized by long periods 
of remission, and types with a more aggressive evo-
lution, with complications and extra-intestinal mani-
festations. Nevertheless, in pregnancy is high the per-
centage of patients who undergo surgery, as a result 
of the severe disease. Many are the difficulties related 
to the management of IBD during pregnancy. For the 
treatment of a pregnant with IBD, a close collabora-
tion of gastroenterologist and gynaecologist should be 
mandatory.
The most important aspects to consider are:
• effect of IBD on pregnant;
• effect of pregnancy on IBD;
• effects of the disease on the foetus;
• medical or surgical treatment.
Family history of the pregnant woman is a crucial 
aspect in the management of the disease. In general, 
the risk of transmitting IBD to the offspring ranges 
from 5% to 10%. If both parents have IBD, the prob-
ability of manifesting the disease is 36%; this indicates 
the importance of genetic transmission (17). The fer-
tility seems to be normal for UC and could be slightly 
decreased for CD. This may be related to the trans-
mission of the inflammatory process in the ovaries and 
the fallopian tubes, or to the poor nutritional intake 
that accompanies the disease (18). In these patients, a 
decreased libido (but also in partner), related to com-
plications of the disease (perianal pain, rectal vaginal 
fistula), could be recognized (18,19).
The European Crohn’s and Colitis Organization 
(ECCO) has announced the publication of new guide-
lines regarding pregnancy and related problems (39). 
Recently, the international scientific literature has ex-
perienced an increase in scientific papers published on 
the subject. We report the Israeli multicenter study 
conducted by Dotan (40) involving 159 mothers with 
IBD compared with 175 healthy mothers. Data col-
lected from this study are summarized as follows:
a) IBD patients conduct a single pregnancy more 
frequently than controls (p = 0.028). One possible ex-
planation for this phenomenon is the reluctance of the 
patients suffering from a such disabling condition to 
become pregnant. These data are also confirmed by 
studies conducted by Mañosa et al. (41) and Selinger 
et al. (42), where 75% of IBD female patients fear of 
transmitting the disease to their children, and 30% of 
them decide not to get pregnant.
b) Mothers with IBD are less prone to breastfeed 
their children, especially when compared to healthy 
ones (p <0.0001). In a recent multicenter study, con-
ducted by de Meij et al. (43), only 9 out of 30 children 
of IBD mothers were breast-fed. ECCO 2010 guide-
lines (39) showed a lower birth weight for those chil-
dren of IBD female patients (p = 0.007). These data 
were also confirmed by a study published by Bortoli et 
al. in 2011 (44).
c) The children of mothers with IBD have a 
greater incidence of congenital anomalies (especially 
limb deformities) (p < 0.035 ). Although some meta-
analyzes have not evidenced a real correlation between 
IBD and the development of congenital anomalies, 
the presence of limb deformity is reported by several 
publications, including the above cited ECCO 2010 
guidelines (39).
d) Those children of IBD mothers show major 
problems in neuromotor development (motor delay, p 
= 0.03) (39). 
e) During pregnancy, a recurrence of disease was 
registered in 30% of cases, occurring more frequently 
in the first quarter (45%). Pregnancy, itself, does not 
increase the risk of recurrence, if conception occurs in 
clinical remission (39).
f ) Children born from mothers with active IBD, 
are more likely premature and show a lower body 
weight. This data was registered especially in those 
patients treated with steroids, and decreased in those 
treated with salicylates or immunosuppressants. The 
multicenter studies conducted by Meij et al. (43) and 
by Casanova et al. (45) showed that Thiopurines are 
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a safe drug during pregnancy. However, the study of 
Jharap et al. (46) reported, in 30 pregnant women ex-
posed to thiopurines, an altered metabolism of these 
drugs. Both values returned normal after childbirth. 
Interestingly, Marchioni et al. (47) demonstrated an 
uncertain safety of anti-TNFα drugs during pregnan-
cy. Similarly, several authors recommend to suspend 
anti-TNFα treatment shortly before delivery. Furter-
more, the study of Zelinková et al. (48) showed, in 31 
pregnant who have discontinued therapy before the 
birth, persistent anti-TNFα drug levels in the um-
bilical cord blood of the foetus. We are waiting for the 
results of the the ongoing prospective study named 
“PIANO” (49), involving 1000 pregnant women, in 
which patients have been exposed immunosuppressive 
and biological drugs.  Pregnant patients with IBD, in a 
state of remission or mild disease have the same risk of 
spontaneous abortion of the general population (20). 
Women with IBD in an active phase at the time of 
conception have a higher risk of spontaneous abortion. 
The risk of foetal death, during pregnancy, or neona-
tal death, increases proportionally with the increase of 
disease activity (60% risk in severe CD, 20-40% risk 
in severe UC, 60% of risk in fulminant UC). Scientific 
literature shows that a non-active disease at concep-
tion is recommended to reduce the risk of foetal com-
plications, such as preterm birth and low birth weight 
(21). Literature does not reveal specific details regard-
ing the type of delivery. To date, gynaecologists prefer 
a natural delivery, if the disease is in a phase of remis-
sion, whereas in a case of active disease (particularly if 
complicated with perianal disease), they recommend 
cesarean delivery (23, 24).
Effects of pregancy on IDB
During pregnancy, no significant differences were 
demonstrated in the course of CD and UC, and the 
risk of exacerbation does not seem to increase. Some 
clinical trials have shown that the development of 
bowel disease during pregnancy does not increase the 
number of relapses, compared to control population. 
However, if the disease is present in the active phase 
at the time of conception, it increases the risk of per-
sistent symptoms and recurrence of 60-70%, especially 
in the first quarter of pregnancy (26, 27). This could be 
due to the discontinuation of drug therapy. There is no 
certainty that voluntary abortion leads to a decrease of 
relapses (27). The prognosis of IBD that begins dur-
ing pregnancy is not worse than others. Perhaps, this 
can be explained by the altered immune response of 
the pregnant, with and a greater immunological toler-
ance which could lead to a reduction of inflammatory 
processes (28).
Farmacological therapy of IBD during pregnancy
There are numerous reports present in the litera-
ture about the safety of drug therapy during pregnancy 
(30). The treatment of IBD in pregnant women was 
based, from the mid-fifties to the mid-nineties, mainly 
on the use of glucocorticosteroids. Subsequently, these 
drugs were associated to immunosuppressants (mainly 
AZA) and antibiotics.
Corticosteroids
Corticosteroids have been used for the treatment 
of various diseases during pregnancy (asthma, rheuma-
toid arthritis). The use of corticosteroids did not show 
an increased risk of foetal malformations. In a study 
conducted by Fraser et al. (35), involving 531 preg-
nant women, the patients received doses of corticoster-
oids in different periods of their pregnancy. Premature 
births, spontaneous abortions and defects in mental 
development were nor observed. When necessary, cor-
ticosteroids can be administered safely to control ac-
tive disease during pregnancy. There is the possibility 
of adrenal gland suppression among infants of mothers 
taking steroids. Therefore, the use of steroids more eas-
ily metabolized by the placenta, such as prednisone or 
prednisolone, is recommended.
5-Aminosalycilates
a) Mesalazine
Mesalazine is a safe drug during pregnancy. Its 
use is not a contraindication for breastfeeding as the 
percentage of drug that passes into breast milk is very 
low (32-33).
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b) Sulfasalazine
Although there are occasional reports of congeni-
tal anomalies associated with the use of sulfasalazine in 
pregnancy, several studies have demonstrated its safe-
ty. Pregnant women treated with sulfasalazine should 
take at least 2 mg of folate supplementation per day, 
as sulfasalazine interferes with the normal folate me-
tabolism (31).
Antibiotics
a) Metronidazole
Metronidazole is the antibiotic most widely used 
in IBD. However, the literature shows reports of fetal 
malformations, although studies have found no rela-
tionship between metronidazole during pregnancy and 
birth defects (29).
b) Ciprofloxacin
A review of the literature showed that the intake 
for a short period of ciprofloxacin in pregnancy is safe, 
although complications can occur such as premature 
birth (34).
Immunosuppressunts
a) Azathioprine/6-Mercaptopurine
Azathioprine passes into the fetal blood in an in-
active form, therefore the fetus is not exposed to the 
effects of the substance. This makes possible its use 
during pregnancy, if indicated. In those cases of clini-
cal remission, it is recommended to stop taking the 
drug before conception (34-36).
b) Methotrexate
Methotrexate is contraindicated during pregnan-
cy. After its assumption, miscarriages in 40% of pa-
tients and fetal abnormalities, including spina bifida, 
in 30% of cases, have been reported (37).
c) Thalidomide
Thalidomide is contraindicated during pregnancy. 
After its administration, spontaneous abortion, fetal 
death in 30% of pregnancies, and cases of fetal limb 
malformation (phocomelia), have been reported (37).
d) Cyclosporine
Cyclosporine is the most used immunosuppres-
sant during pregnancy. This drug can be used in severe 
or fulminant ulcerative colitis, for the purpose of de-
lay or avoid surgery. Mosckoviz DN et al. conducted a 
study (30) on the use of cyclosporine in IBD in the 
acute phase, and noted the possibility of spontaneous 
abortions but no congenital anomaly or nephrotoxicity.
e) Infliximab
Infliximab is a chimeric monoclonal antibody 
(human/murine), which acts blocking selectively the 
action of TNF-α, one of the most powerful pro-in-
flammatory and cytolesive cytokine. Several studies 
have demonstrated that the intravenous infusion of 
infliximab in patients suffering from CD, determines a 
regression of inflammation in a statistically significant 
number of patient, in comparison with placebo group 
(27). Infliximab side effects on pregnancy are not com-
pletely known. Spontaneous abortion or even Fallot’s 
tetralogy have been described (38).
Conclusions
There are no statistical significant differences, in 
terms of complications or disease recurrence during 
pregnancy or deliver, in IBD patients in comparison 
with general population. Importantly, miscarriages or 
premature births likely depends on disease activity at 
the time of conception. The standard treatment with 
steroids and 5-ASA has no harmful effects on the foe-
tus, and the maintenance of clinical remission is the 
most important factor for a regular course of pregnan-
cy and childbirth.
We can summarize the practical recommenda-
tions as follows:
1.  a new pregnancy should start during an in inactive 
phase of the disease;
2.  during pregnancy, a standard therapy with salazopy-
rine or 5ASA should be continued, increasing their 
dosages or adding systemic steroid therapy in case 
of disease relapse;
3.  is useful to program a tight control obstetrician in 
the third quarter;
4.  the mode of delivery depend on the activity of the 
disease but especially by the perineal obstetric con-
ditions.
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